Karl David Kieburtz, M.D., M.P.H.
Viewing information for Patients. See information for Researchers.
Contact
University of Rochester
School of Medicine and Dentistry
601 Elmwood Ave, Box 673
Rochester, New York 14642
Fax: 585 341-7510
Current Appointments
- Director - Center for Human Experimental Therapeutics (SMD)
- Professor - Department of Neurology (SMD)
- Professor - Department of Environmental Medicine (SMD)
- Professor - Department of Community and Preventive Medicine (SMD)
| Education | ||
|---|---|---|
| MD Medicine | Univ Rochester Sch Med/Dent | 1985 |
| BA Neuroscience | Amherst College | 1980 |
| Awards and Honors | |
|---|---|
| HONORS: Phi Beta Kappa, Amherst College, 1980; Frank Dow Award in Chemistry, Amherst College, 1980; Logan Clendenning Fellowship in the History of Medicine, 1982; George W. Merck Dean's Teaching Scholar, University of Rochester School of Medicine 1994-1997; The Best Doctors in America, Woodward/White, Inc., 2nd edition, 1994 | |
| Medical Director and Steering Committee member, Deprenyl and Tocopherol Antioxidant Therapy of Parkinsonism (DATATOP), NS24778, NINDS, NIH. 11/89-4/94, total costs $13.2 million. | |
| Principal Investigator, Dideoxyinosine treatment of AIDS Dementia, industry sponsored clinical trial, 10/90-11/91, total costs $12,000. | |
| Medical Director and Steering Committee member, Parkinson Study Group START clinical trials, industry sponsored, 11/1/90-4/30/92, total costs $2.2 million. | |
| Member, Neurology Core Committee, AIDS Clinical Trial Group, National Institute of Allergy and Infectious Disease, NIH, 7/90-7/94, 2UO1AI27658 | |
| Medical Director and Steering Committee member, Parkinson Study Group ROADS clinical trial, 4/92-4/94, industry sponsored, total costs $850,000. | |
| Medical Director, Parkinson Study Group, BLIND-DATE clinical trial, 3/93-1/95, industry sponsored, total costs $4 million. | |
| Principal Investigator, Glutamate Antagonist Tolerability in Huntington's Disease, industry sponsored clinical trial, 7/1/93-6/30/94, total costs $225,000. | |
| Medical Director, Parkinson Study Group, STEP-UP clinical trial, 10/93-6/95, industry sponsored, total costs $2.2 million. | |
| Sub-proposer and Consultant, European Network for Striatal Transplantation in Huntington's Disease (NEST-HD): preclinical development and clinical trial methodology, sponsored by the European Economic Community, total costs 200,000 ECU. | |
| Site Principal Investigator, Experimental Therapeutics of HIV Neurology (part of Neurologic AIDS Research Consortium Program Project, David Clifford, PI), NINDS, NIH, total costs $120,000, 12/1/93-11/30/95. | |
| Medical Director, Parkinson Study Group, SEESAW clinical trial, 11/93-12/95, industry sponsored, total costs $2.7 million. | |
| Co-Principal Investigator (L Epstein PI), Dana Foundation Consortium For The Treatment of HIV Dementia And Related Disorders, 1/94-12/96, total costs $855,000. | |
| Study Chair, A Double Blind Study of Amitriptyline and Mexilitine for Painful HIV Neuropathy. AIDS Clinical Trials Group, Protocol 242, 2/94-2/96. | |
| Medical Director (J Friedman PI), Clozapine for Psychosis in PD. FDA, Orphan Drug Div. 7/94-6/97, total direct costs $300,000. | |
| Medical Director (I Shoulson PI) Investigation of Tolerability of OPC-14117 in Huntington's disease. 9/94-9/95, total costs $850,000. | |
| Principal Investigator, Trial of a Glutamate Antagonist in PD and MSA, 9/95-9/96, industry sponsored, total cost $100,000. | |
| Director of Coordination Center (K Marek PI), Evaluation of SPECT Imaging in The Diagnosis of PD, 9/95-9/96, industry sponsored, total cost $1,000,000. | |
| Director of Coordination Center (I Shoulson PI), Comparison of Levodopa and a Dopamine Agonist in PD, 10/95-10/02, industry sponsored, total cost $8,000,000. | |
| Director of Coordination Center (C Tanner PI), Study of a Dopamine Agonist in Minority Persons, 10/95-3/97, total costs $1,000,000. | |
| Director of Coordination Center (R Kurlan, PI), Treatment of ADHD in Children with Tourette's, 7/96-7/99, NIH NINDS, RO1 NS33654. | |
| Principal Investigator, Interaction Study of Remacemide and Levodopa in Parkinson's Disease, 10/96-11/97, industry sponsored, total costs $500,000. | |
| Project Principal Investigator (D Clifford, Washington University, PPG PI), NIH, P01 NS32228, Clinical Trials Unit in HIV Dementia, NINDS, 12/93-4/02, total costs $850,000. | |
| Principal Investigator, Co-Enzyme Q10 and Remacemide Evaluation in Huntington's Disease, NIH, RO1 NS35284, 5/97-5/01, total costs $6.9 million. | |
| Data Management Core Director (L Epstein PI), Neurocognitive Function, HIV Load and Surrogate Markers (NEAD), NIH, P01 NS36519-01A1, 2/98-1/03, total costs $4.5 million. | |
| Coordination Center Director (S Fahn PI), NIH, R01 NS34796-01A1, Earlier vs. Later L-dopa in Parkinson's Disease, 6/98-6/01, total costs $6 million. | |
| Co-Principal Investigator (C Shults PI), NIH R01 NS36714, Effects of Coenzyme Q10 in Patients With Early, Untreated Parkinson's Disease, 6/98-6/01, total costs $1,984,893. | |
| Principal Investigator, NINDS, NS02122, Midcareer Investigator Award in Patient-Oriented Research, 1/99-12/04, total costs $310,649. | |
| Coordination Center Director (J Engel PI), NIH R21 NS37897, A Multi-center Randomized Clinical Trial for Early Treatment of Epilepsy, 7/99-6/00, total costs $254,141. | |
| Chair, Safety Monitoring Committee (L Thal, PI) 5U01-AG010483 Alzheimer's Disease Cooperative Study, 9/01-6/12, total Costs $15,403. | |
| Coordination Center Director, Topical Dopamine Agonist in PD, industry sponsored, 6/99-12/00, total costs $2 million. | |
| Coordination Center Director, Monoamine Oxidase Inhibitor in PD, industry sponsored, 10/97-10/00, $5 million. | |
| Coordination Center Director, Ethylester of Levodopa in PD, industry sponsored, 6/99-6/02, $4 million. | |
| Coordination Center Director (J Engel PI), NIH R21 NS42372, Early Randomized Surgical Epilepsy Trial, 7/01-6/06, total costs $628,749. | |
| Project Co-PI (H Gelbard PI), Targeted Neuroprotection for HIV-1 Associated Neurologic Disease, NIH PO1 MH64570, 7/01-6/05, $1,577,926. | |
| Principal Investigator, Neuroprotection Studies in PD: A Coordinating Center, NIH, NINDS NS43128, 9/01-7/06, $6,539,243. | |
| Coordination Center Director (J Paulsen PI), Neurobiological Predictors of Huntington's Disease (PREDICT-HD), NINDS NS40068, 11/01-10/06, $7,999,975. | |
| Coordination Center Director (I Shoulson, PI), Prospective Huntington At-Risk Observational Study (PHAROS), Huntington's Disease Society of America and Hereditary Disease Foundation, 5/99-12/01, $1,000,000. | |
| Coordination Center Director (I Shoulson, PI), Prospective Huntington At-Risk Observational Study (PHAROS), NIH/NHGRI/NINDS R01HG02449, 9/30/02-6/30/07, $6,878,408 | |
| Coordination Center Director (I Shoulson, PI), A multicenter placebo-controlled efficacy and safety trial of an experimental membrane-stabilizing drug ethyl-EPA in ambulatory Huntington's disease patients, 3/05-6/08, $5,923,456 | |
| Coordination Center Director (M Cudkowicz, PI), Double blind study of minocycline in Huntington's disease, FD-R-02588, 8/05-8/08, $206,589 | |
| Principal Investigator, Multi-Center Phase 1-2A Open-Label Dose-Escalation & Randomized, Double-Blind, Placebo-controlled Study of Dimebon in Subjects with Huntington's Disease (DIMOND), industry sponsored, 2/06-5/07, $1,716,766 | |
| Principal Investigator, A randomized, double-blind, active and placebo controlled, efficacy study of pramipexole in subjects with Parkinson's disease, industry sponsored, 3/1/06-1/08, $3,669,313 | |
| Instructor (D Guzick, PI), The University of Rochester's Clinical and Translational Science Institute, UL1 RR024160, KL2 RR024136, TL1 RR024135, 9/06-6/11, $4,668,817 | |
| Principal Investigator, Neuroprotection Studies in PD: A Coordinating Center, NIH, NINDS NS43128, 12/1/06-11/30/11, $1,490,740. | |
| Principal Investigator, NINDS, NS02122, Midcareer Investigator Award in Patient-Oriented Research, 1/99-12/04, total costs $310,649. | |
| Coordination Center Director (J Engel PI), NIH R21 NS37897, A Multi-center Randomized Clinical Trial for Early Treatment of Epilepsy, 7/99-6/00, total costs $254,141. | |
